# Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery

> **NCT04897126** · PHASE4 · COMPLETED · sponsor: **Shanghai Hutchison Pharmaceuticals Limited** · enrollment: 240 (actual)

## Conditions studied

- Ischemia With Non-Obstructive Coronary Artery
- Angina Pectoris
- Coronary Heart Disease
- X Syndrome, Angina

## Interventions

- **RADIATION:** Shexiang Baoxin pill（MUSKARDIA）
- **RADIATION:** Placebo

## Key facts

- **NCT ID:** NCT04897126
- **Lead sponsor:** Shanghai Hutchison Pharmaceuticals Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-11
- **Primary completion:** 2023-07-04
- **Final completion:** 2023-10-25
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2024-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04897126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04897126, "Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04897126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*